ARCHIVES

Merck Serono Cancels Tecemotide Program In NSCLC, Including Two Phase III Trials

This article is from The Cancer Letter archive.

Vol. 37 No. 9 | September 26, 2014

Download PDF Visit The Full Archive

Related Articles

April issue of Business & Regulatory Report included (8 additional pages).

April 30, 2004

Two New Modalities Promising For Relapsed/Refractory NHL

January 28, 2005

CMS To Begin National Coverage Analysis Of Provenge

July 2, 2010

Leyland-Jones Named Director of Emory’s Winship Cancer Institute

November 17, 2006

In Brief: FASEB Report On Diet and Cancer Mortality Available; Don Poppke AO of Nursing Center

March 6, 1987

BRAF Mutation Testing Classifies Indeterminate FNA Samples

March 29, 2013